Other Information.
+Added: Insider Trading Arrangements
+Added: During the quarter ended August 31, 2023, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) or the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" (each as defined in Item 408(a) and (c), respectively, of Regulation S-K).
+Added: Table of Content
EXHIBIT INDEX Incorporated by Reference
Description Form Exhibit Filing Date
+Added: 2.1 Asset Purchase Agreement dated as of June 8, 2023 by and between AngioDynamics, Inc.
+Added: and Merit Medical Systems, Inc.
+Added: 8-K 2.1 June 14, 2023
31.1 Certification pursuant to Rule 13a-14(a) or 15d-14 under the Securities Exchange Act of 1934
8 unchanged sentences
101.PRE XBRL Presentation Linkbase Documents
+Added: Table of Content
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ANGIODYNAMICS, INC.
−Removed: March 31, 2023 / S / JAMES C.
+Added: October 5, 2023 / S / JAMES C.
Clemmer, President,
1 unchanged sentence
(Principal Executive Officer)
−Removed: March 31, 2023 / S / STEPHEN A.
+Added: October 5, 2023 / S / STEPHEN A.
Trowbridge, Executive Vice President,
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.